

Special Issue

Women's Disease and Related Vaccine

Message from the Guest Editor

Dear Colleague, In gynecology, when considering any women's disease that could be avoided or treated with a specific related vaccine, clearly the most representative one is the cervical cancer and the HPV vaccine. During the last 10 years, we have observed a great evolution in HPV vaccines: from those based on two HPV serotypes to those based on nine HPV serotypes; from preventive vaccines to the new therapeutic vaccines which are under development; from scarce knowledge about the immunity response and its duration to new findings and crossed immunity for other serotypes not contained in the original vaccine. All these research lines and new findings make this Special Issue an opportunity to communicate promising research lines, new concepts, results of immunization on different populations (based on age, previous surgical treatments, immunosuppressed patients, etc.), and every single development related to HPV vaccines. We hope all authors and researchers consider this opportunity to publish their work in this *Vaccines* journal.

Guest Editor

Dr. Ignacio Zapardiel

Gynecologic Oncology Unit, La Paz University Hospital, 28046 Madrid, Spain

Deadline for manuscript submissions

closed (30 April 2021)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/57787

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).